Comparing Jushi (JUSHF) and Its Competitors

Jushi (OTCMKTS:JUSHF) is one of 55 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its rivals? We will compare Jushi to similar companies based on the strength of its analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Volatility and Risk

Jushi has a beta of -0.16, indicating that its share price is 116% less volatile than the S&P 500. Comparatively, Jushi’s rivals have a beta of 1.36, indicating that their average share price is 36% more volatile than the S&P 500.

Institutional and Insider Ownership

21.7% of Jushi shares are owned by institutional investors. Comparatively, 16.1% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 21.0% of Jushi shares are owned by insiders. Comparatively, 22.4% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Jushi and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jushi	-24.16%	-320.66%	-10.31%
Jushi Competitors	-45.53%	-60.43%	-9.08%

Earnings and Valuation

This table compares Jushi and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Jushi	$269.45 million	-$65.10 million	-2.03
Jushi Competitors	$298.06 million	-$154.30 million	-10.35

Jushi’s rivals have higher revenue, but lower earnings than Jushi. Jushi is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Jushi and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jushi	0	2	0	0	2.00
Jushi Competitors	246	546	918	66	2.45

As a group, “Medicinals & botanicals” companies have a potential upside of 74.79%. Given Jushi’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Jushi has less favorable growth aspects than its rivals.

Summary

Jushi rivals beat Jushi on 9 of the 13 factors compared.

Jushi Company Profile

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of medical and adult-use products. It focuses on building a portfolio of cannabis assets in various jurisdictions in Pennsylvania, Virginia, Ohio, Illinois, California, Nevada, and Massachusetts. The company also offers hemp-based CBD products, including cannabis dry flower, vaporizer forms of cannabis, edibles, cannabis oil in capsules, tinctures, cannabis in topical products, and other cannabis products, as well as vape cartridges, disposables, and concentrates under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. In addition, it operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. The company is headquartered in Boca Raton, Florida.